Supplementary file 1_The efficacy and safety of Fuzheng traditional Chinese medicine injections in the treatment of acute ischemic stroke: a systematic review and network meta-anal... by Qiaosheng Ren (20532449)

“…The study showed that Mailuoning injection (MLN), Huangqi injection (HQ), Shengmai injection (SHM), Ciwujia injection (CWJ), Shenfu injection (SF), and Shenmai injection (SM) combined with CT significantly improved performance compared with CT alone in treating AIS. …”

Table 1_Comparative study of endophytic bacterial strains from non-host crops for enhancing plant growth and managing early blight in tomato.docx by Aditya Kukreti (20129547)

“…Field trials confirmed the glasshouse findings, showing reduced early blight and improved growth parameters in tomato where the ST + SD + FS combination emerged as the most effective treatment for all endophytes showing 1.06–1.88 fold increase in fruit yield per plant and 28.92–32.52% decrease in PDI compared to untreated control. …”

Data Sheet 1_Combined effect of esaxerenone and dapagliflozin on aldosterone-mediated sodium reabsorption and potassium excretion.docx by Motonobu Nakamura (5944421)

“…TWIK-1 expression did not significantly decrease in rats continuously treated with ESX and Dapa compared with that in rats treated with ESX alone.…”

Table_1_The safe lowest effective power of subthreshold micropulse laser treatment in Chinese patients with acute or chronic central serous chorioretinopathy.DOCX by Ting Xie (191025)

“…The baseline characteristics were balanced between the five groups (all p > 0.05). The decrease of CMT and the improvement of BCVA were related to the CMT at baseline (all p < 0.05). …”

Table 1_Evaluating the effectiveness of integrated care in targeted therapy for patients with chronic lymphocytic leukemia.docx by Xin Liu (43569)

“…In addition, comprehensive nursing significantly improves patients’ quality of life, improves physical fitness, reduces anxiety and depression levels, especially in the six months and one year after treatment.…”

Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients by Sana Mohsin (19773969)

“…</p> <p><b>Results:</b> 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33–0.82); <i>p</i> = 0.005; I²= 32%], HF hospitalization [RR = 0.20 (0.04–1.02); <i>p</i> = 0.05; I²= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20–1.16); <i>p</i> = 0.11, I²= 0%].…”

Data Sheet 1_Efficacy and safety of reduning injection for severe pneumonia: a systematic review and meta-analysis.docx by Yan Wang (15435)

“…Moreover, no significant improvement was observed in the Acute Physiology and Chronic Health Evaluation II (APACHE II) scale compared to the control group [MD = −2.45 points; 95% CI (−6.07, 1.17); p = 0.19]. …”

Image 1_Myristic acid beneficially modulates intervertebral disc degeneration by preventing endplate osteochondral remodeling and vertebral osteoporosis in naturally aged mice.pdf by Yan Gong (103494)

“…Additionally, MA notably inhibited osteoclast activity, as evidenced by a decrease in the number of osteoclasts and a significant suppression of F-actin formation. …”

Table 1_Evaluation of environmental risk factors associated with survival of generic E. coli in organic integrated crop-livestock systems in California and Minnesota.docx by Annette Kenney (14843218)

“…Concentrations (Most Probable Number/100 g) of gEc in grazed soil returned to levels comparable to non-grazed or fallow treatments within 87–147 days post-graze (DPG) in both years, with a significant decrease predicted after 32 DPG. Interestingly, non-O157 STEC was detected in soil even after concentrations of gEc declined 115–147 DPG.…”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_Enabling immune checkpoint blockade efficacy in T-lymphopenia by restoring CD8 T cell dynamics with IL-7 cytokine therapy.docx by Yeon-Woo Kang (18285202)

“…The combination of rhIL-7-hyFc and anti-PD-1 therapy resulted in significant tumor regression and improved mouse survival.…”

Image 5_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.png by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 9_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 1_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.jpeg by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 2_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”

Image 8_Unexpected estradiol decline during ovarian stimulation monitoring affects cumulative live birth.tiff by Haixiao Chen (12565087)

“…In both unmatched and matched cohorts, the CLBRs were significantly decreased (unmatched cohort: 66.3% versus 55%, P<0.001, adjusted OR 0.83, 95% CI: 0.76,0.91; matched cohort: 59% versus 55%, P = 0.003, adjusted OR 0.84, 95%CI: 0.75,0.94). …”